China SXT Pharmaceuticals (SXTC) Competitors $0.48 -0.05 (-10.36%) (As of 12:38 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsShort InterestTrends SXTC vs. ATHE, CDT, UPXI, RNAZ, ABVC, CYCN, OBSV, COEP, PULM, and VIRXShould you be buying China SXT Pharmaceuticals stock or one of its competitors? The main competitors of China SXT Pharmaceuticals include Alterity Therapeutics (ATHE), Conduit Pharmaceuticals (CDT), Upexi (UPXI), TransCode Therapeutics (RNAZ), ABVC BioPharma (ABVC), Cyclerion Therapeutics (CYCN), ObsEva (OBSV), Coeptis Therapeutics (COEP), Pulmatrix (PULM), and Viracta Therapeutics (VIRX). These companies are all part of the "pharmaceutical products" industry. China SXT Pharmaceuticals vs. Alterity Therapeutics Conduit Pharmaceuticals Upexi TransCode Therapeutics ABVC BioPharma Cyclerion Therapeutics ObsEva Coeptis Therapeutics Pulmatrix Viracta Therapeutics China SXT Pharmaceuticals (NASDAQ:SXTC) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, community ranking, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment. Does the MarketBeat Community favor SXTC or ATHE? China SXT Pharmaceuticals received 79 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. Likewise, 61.65% of users gave China SXT Pharmaceuticals an outperform vote while only 60.00% of users gave Alterity Therapeutics an outperform vote. CompanyUnderperformOutperformChina SXT PharmaceuticalsOutperform Votes8261.65% Underperform Votes5138.35% Alterity TherapeuticsOutperform Votes360.00% Underperform Votes240.00% Which has more volatility & risk, SXTC or ATHE? China SXT Pharmaceuticals has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Which has preferable earnings & valuation, SXTC or ATHE? China SXT Pharmaceuticals has higher revenue and earnings than Alterity Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChina SXT Pharmaceuticals$1.93M1.11-$3.10MN/AN/AAlterity TherapeuticsN/AN/A-$12.54MN/AN/A Does the media prefer SXTC or ATHE? In the previous week, Alterity Therapeutics had 1 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 2 mentions for Alterity Therapeutics and 1 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 0.00 equaled Alterity Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China SXT Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is SXTC or ATHE more profitable? Company Net Margins Return on Equity Return on Assets China SXT PharmaceuticalsN/A N/A N/A Alterity Therapeutics N/A N/A N/A Do insiders and institutionals have more ownership in SXTC or ATHE? 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend SXTC or ATHE? Alterity Therapeutics has a consensus target price of $4.00, indicating a potential upside of 241.88%. Given Alterity Therapeutics' higher probable upside, analysts plainly believe Alterity Therapeutics is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AAlterity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryChina SXT Pharmaceuticals beats Alterity Therapeutics on 6 of the 10 factors compared between the two stocks. Ad Porter & CompanyThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly repeat itself with the AI frenzy. I urge you to watch it before you invest another cent. Again, to be clear, I’m no Chicken Little. Far from it. So go here now to read my new report The Big AI Die-Up… while you still can. Get China SXT Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SXTC vs. The Competition Export to ExcelMetricChina SXT PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.15M$6.69B$4.97B$8.42BDividend YieldN/A7.94%7.49%4.16%P/E RatioN/A10.88121.3416.44Price / Sales1.11356.611,519.5791.98Price / CashN/A46.0936.9033.53Price / Book0.025.324.585.14Net Income-$3.10M$148.76M$112.22M$223.04M7 Day Performance-10.17%1.76%115.58%3.22%1 Month Performance-26.29%13.95%129.27%8.47%1 Year Performance-77.06%35.21%157.18%28.62% China SXT Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SXTCChina SXT Pharmaceuticals0.2478 of 5 stars$0.48-10.4%N/A-77.1%$1.93M$1.93M0.0090News CoverageATHEAlterity Therapeutics2.6825 of 5 stars$1.17+1.7%$4.00+241.9%-51.3%$8.55MN/A0.0010CDTConduit PharmaceuticalsN/A$0.09-3.2%N/A-93.0%$8.46MN/A0.003Gap DownUPXIUpexi2.2965 of 5 stars$8.04+2.6%$25.00+210.9%-64.4%$8.39M$83.98M0.00130Gap DownRNAZTransCode Therapeutics2.2522 of 5 stars$0.48+3.2%$3.00+525.0%-96.6%$8.29MN/A0.009Gap UpABVCABVC BioPharmaN/A$0.66-4.5%N/A-43.6%$8.20M$150,000.00-0.4030Gap UpCYCNCyclerion Therapeutics0.8846 of 5 stars$2.95+2.1%N/A+26.1%$8.00M$1.62M0.0030Upcoming EarningsGap UpHigh Trading VolumeOBSVObsEvaN/A$0.10-15.5%N/AN/A$7.94M$20.11M-0.1150News CoverageGap UpCOEPCoeptis TherapeuticsN/A$0.20-1.0%N/A-79.6%$7.87M$80,000.00-0.422Gap DownPULMPulmatrix0.1853 of 5 stars$2.13-3.2%N/A+11.5%$7.77M$7.30M-0.7220Analyst ForecastNews CoverageVIRXViracta Therapeutics3.2547 of 5 stars$0.19-3.7%$5.50+2,729.2%-71.5%$7.66MN/A-0.1720Gap Down Related Companies and Tools Related Companies Alterity Therapeutics Alternatives Conduit Pharmaceuticals Alternatives Upexi Alternatives TransCode Therapeutics Alternatives ABVC BioPharma Alternatives Cyclerion Therapeutics Alternatives ObsEva Alternatives Coeptis Therapeutics Alternatives Pulmatrix Alternatives Viracta Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SXTC) was last updated on 11/4/2024 by MarketBeat.com Staff From Our PartnersCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | Sponsored[Charles Payne Live Event] Click to Confirm Your RSVPThe Blueprint to Protect Your Portfolio Charles Payne reveals a strategy few investors know about Unstoppable Prosperity | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China SXT Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China SXT Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
